iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio, a clinical-stage biotechnology company focused on long-acting antibody therapeutics for obesity and cardiometabolic diseases, has appointed Dr. Molly Carr as Chief Medical Officer. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, having held senior roles at major biopharmaceutical companies. Her leadership i…